एपीए उद्धरण

Ray, K. K., Leiter, L. A., Müller‐Wieland, D., Cariou, B., Colhoun, H. M., Henry, R. R., . . . Del Prato, S. (2018). Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial. Diabetes Obes Metab.

शिकागो स्टाइल उद्धरण

Ray, Kausik K., et al. "Alirocumab Vs Usual Lipid‐lowering Care As Add‐on to Statin Therapy in Individuals With Type 2 Diabetes and Mixed Dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA Randomized Trial." Diabetes Obes Metab 2018.

एमएलए उद्धरण

Ray, Kausik K., et al. "Alirocumab Vs Usual Lipid‐lowering Care As Add‐on to Statin Therapy in Individuals With Type 2 Diabetes and Mixed Dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA Randomized Trial." Diabetes Obes Metab 2018.

चेतावनी: ये उद्धरण हमेशा 100% सटीक नहीं हो सकते हैं.